Altesa

BioSciences

Developing Drugs to Treat Respiratory Viruses and Global Viral Threats

Altesa Biosciences, Inc., is a clinical-stage biopharmaceutical company developing drugs to treat RNA viruses, which are responsible for 80% of viral diseases worldwide. Among these viruses are Rhinovirus (primary cause of the common cold), Influenza, Respiratory Syncytial Virus (RSV), Dengue virus, Yellow Fever virus, Ebola virus, and SARS-CoV-2 (COVID-19).

 

Dr George Painter and Dr Dennis Liotta, Altesa BioScience’s scientific co-founders, lead the Drug Innovation Ventures at Emory University (DRIVE) and are responsible for some of the most impactful virus treatments in the world, including emtricitabine for HIV/AIDS, and molnupiravir for COVID-19.

Altesa’s mission is to accelerate the clinical development and commercialization of the DRIVE’s next six molecules that could follow in the footsteps of their previous blockbusters.

Altesa is led by its CEO, Brett P. Giroir, MD – former Assistant Secretary for Health and Acting FDA Commissioner – and a highly successful and experienced management team advised by world leaders in science and clinical medicine.

Altesa Leadership Team

Brett P. Giroir, MD

Chief Executive Officer and Acting Chief Medical Officer

  • Former US Assistant Secretary for Health and Admiral, USPHS
  • Former Acting FDA Commissioner
  • Former CEO, ViraCyte (now AlloVir)

George R. Painter, PhD

Founder and Co-Chair, Scientific Advisory Board

  • Former Director of Virology, Burroughs Wellcome Co.
  • Former International Deputy Therapeutic Head for Antiviral Research, GlaxoWellcome
  • Co-founder & EVP R&D, Triangle Pharmaceuticals (sold to Gilead Sciences, 2002)
  • Co-founder & CEO, Chimerix, Inc. (NASDAQ: CMRX)
  • Co-Founder & CEO, Drug Innovation Ventures at Emory (DRIVE)
  • Co-Inventor brincidofovir and molnupiravir

Dennis C. Liotta, PhD

Founder and Member, Scientific Advisory Board

  • Co-founder, Pharmasset
  • Co-founder, DRIVE and Emory Institute for Drug Development
  • Co-inventor emtricitabine and lamivudine

Seth Rudnick, MD

Founder and Chair, Board of Directors

  • Chairman, DRIVE Advisory Board
  • Former Canaan Partners, General Partner
  • Former CytoTherapeutics, CEO & Chairman
  • Forbes Midas List: top deal makers in biotechnology (named twice)

John M. Clerici, JD

Founder and Chief Operating Officer

  • Founder, Tiber Creek Partners LLC, Raised over $6B in Non- Dilutive Capital
  • Former Partner & Life Sciences Chair, McKenna Long & Aldridge LLP
  • Former Board Member, Aeolus Pharmaceuticals Inc.

“My number one priority is to make a difference in patients’ lives. I am confident that we can develop safe and highly effective treatments against a broad variety of pathogenic viruses, just as we have already done for HIV/AIDS and COVID-19.”

 

George Painter, PhD

Co-Founder, Altesa BioSciences
“My number one priority is to make a difference in patients’ lives. I am confident that we can develop safe and highly effective treatments against a broad variety of pathogenic viruses, just as we have already done for HIV/AIDS and COVID-19.”

 

George Painter, PhD

Co-Founder, Altesa BioSciences

Altesa’s Value Proposition

Vapendavir, a Phase 2 Clinical Asset with an excellent safety profile and positive virologic data in human trials. Vapendavir is a broad-spectrum capsid inhibitor with potent activity across all rhinovirus families and other respiratory enteroviruses.

Altesa’s Value Proposition

Proven Platform for mechanism-based development of novel broad-spectrum antivirals, including some of world’s most successful anti-viral drugs.

Altesa’s Value Proposition

IND Enabled Anti-Viral Drug from Emory/DRIVE (ALT-2023): a Broad-Spectrum Nucleoside Analog Active Across Most Enteroviruses & Flaviviruses.

Altesa’s Value Proposition

Pre-Negotiated Options & Sponsored Research Agreement with Emory/DRIVE provides unique access to R&D pipeline, and world-class industry-trained scientists.